Literature DB >> 15621262

Stimulation of bone formation by zoledronic acid in particle-induced osteolysis.

Christian Wedemeyer1, Fabian von Knoch, Andreas Pingsmann, Gero Hilken, Christoph Sprecher, Guido Saxler, Frank Henschke, Franz Löer, Marius von Knoch.   

Abstract

We investigated the effect of a single subcutaneous dose of zoledronic acid on particle-induced osteolysis and observed excessive regional new bone formation. We utilized the murine calvarial osteolysis model and polyethylene particles in C57BL/J6 mice. Twenty-eight mice were used, seven per group. Specimens were stained with Giemsa dye. The osteoid tissue area was determined. Bone thickness was measured as an indicator of bone growth. Net bone growth was significantly increased in animals with zoledronic acid treatment: 0.02 mm(2)+/-0.03 mm(2) in animals with particle implantation only (group 2), 0.25 mm(2)+/-0.08 mm(2) with particle implantation and zoledronic acid treatment directly after surgery (group 3; p=0.0018), and 0.21 mm(2)+/-0.11 mm(2) with particle implantation and zoledronic acid treatment on the fourth postoperative day (group 4; p=0.0042). The mean bone thickness was 0.2 mm+/-0.04 mm (range 0.17 mm-0.31 mm) in group 1 (sham controls) and 0.16 mm+/-0.02 mm (range 0.14 mm-0.19 mm) in group 2, 0.31 mm+/-0.04 mm (range 0.28 mm-0.39 mm) in group 3, and 0.29 mm+/-0.02 mm (range 0.28 mm-0.34 mm) in group 4. Student's t-test revealed a statistically significant difference between groups 2 and 3 (p=0.00042), and groups 2 and 4 (p=0.0019). In conclusion, our observational study suggests that zoledronic acid may stimulate bone apposition locally in the process of particle-induced osteolysis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15621262     DOI: 10.1016/j.biomaterials.2004.09.026

Source DB:  PubMed          Journal:  Biomaterials        ISSN: 0142-9612            Impact factor:   12.479


  5 in total

1.  The effect of zoledronate during bone healing.

Authors:  Marcos Almeida Matos; Uenis Tannuri; Roberto Guarniero
Journal:  J Orthop Traumatol       Date:  2010-02-19

2.  Systemic zoledronate treatment both prevents resorption of allograft bone and increases the retention of new formed bone during revascularization and remodelling. A bone chamber study in rats.

Authors:  Jörgen Astrand; Anna Kajsa Harding; Per Aspenberg; Magnus Tägil
Journal:  BMC Musculoskelet Disord       Date:  2006-08-04       Impact factor: 2.362

3.  Stevioside Prevents Wear Particle-Induced Osteolysis by Inhibiting Osteoclastogenesis and Inflammatory Response via the Suppression of TAK1 Activation.

Authors:  Jiahong Meng; Chenhe Zhou; Bin Hu; Mengmeng Luo; Yute Yang; Yangxin Wang; Wei Wang; Guangyao Jiang; Jianqiao Hong; Sihao Li; Haobo Wu; Shigui Yan; Weiqi Yan
Journal:  Front Pharmacol       Date:  2018-09-26       Impact factor: 5.810

4.  Jatrorrhizine Hydrochloride Suppresses RANKL-Induced Osteoclastogenesis and Protects against Wear Particle-Induced Osteolysis.

Authors:  Hui Li; Jing Wang; Qiwen Sun; Gang Chen; Shengnan Sun; Xuemei Ma; Haiwen Qiu; Xuerong Liu; Liangyi Xu; Mei Liu
Journal:  Int J Mol Sci       Date:  2018-11-21       Impact factor: 5.923

5.  Zoledronic acid and teriparatide have a complementary therapeutic effect on aseptic loosening in a rabbit model.

Authors:  Peng Wang; Guang-Qian Shang; Shuai Xiang; Hai-Ning Zhang; Ying-Zhen Wang; Hao Xu
Journal:  BMC Musculoskelet Disord       Date:  2021-06-24       Impact factor: 2.362

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.